Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients

Rui Liu, Fan Yang, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2023-184692

Published: 2023

Journal Articles

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Shaomei Feng, Teng Xu, Haidi Liu, Peihao Zheng, Lixia Ma, Hui SHI, Tong Wu, Fan Yang, Kai HU, Xiaoyan Ke

Blood (2023) 142 (Supplement 1): 4638.

https://doi.org/10.1182/blood-2023-182797

Published: 2023

Journal Articles

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Fan Yang, Rui Liu, Teng Xu, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui SHI, Lixia Ma, Guoai Su, Biping Deng, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 6922.

https://doi.org/10.1182/blood-2023-177836

Published: 2023

Journal Articles

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Yingtong Chen, Ping Yang, Jing Wang, Shuang Gao, Xiaoyan Ke, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4416.

https://doi.org/10.1182/blood-2023-183096

Published: 2023

Journal Articles

Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma

Lixia Ma, Xiaoyan Ke, Kai HU

Blood (2023) 142 (Supplement 1): 3434.

https://doi.org/10.1182/blood-2023-184412

Published: 2023

Journal Articles

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

Teng Xu, Fan Yang, Rui Liu, Zhonghua Fu, Na Li, Xiaoyan Ke, Shaomei Feng, Biping Deng, Kai Hu

Blood (2023) 142 (Supplement 1): 3513.

https://doi.org/10.1182/blood-2023-185590

Published: 2023

Journal Articles

The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors

Hui SHI, Kai HU, Xiaoyan Ke

Blood (2023) 142 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2023-184452

Published: 2023

Journal Articles

Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

Li Bao, Kai HU, Xiaoyan Ke, Yutong Wang, Mengzhen Wang, Lei Shi, Kai Sun

Blood (2023) 142 (Supplement 1): 6095.

https://doi.org/10.1182/blood-2023-181041

Published: 2023

Journal Articles

Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

Jun Zhu, Yuqin Song, Jianyong Li, Keshu Zhou, Xiaoyan Ke, Zhen Cai, Huilai Zhang, Tingting Yao, Zhen Xia, Yiqiu Wang, Peiqiong Lai, Xiaofeng Liu

Blood (2022) 140 (Supplement 1): 6496–6497.

https://doi.org/10.1182/blood-2022-157057

Published: 2022

Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Blood (2022) 140 (Supplement 1): 573–576.

https://doi.org/10.1182/blood-2022-163371

Published: 2022

Journal Articles

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui SHI, Biping Deng, Xiaoyan Ke, Tong Wu, Kai Hu

Blood (2022) 140 (Supplement 1): 10384–10385.

https://doi.org/10.1182/blood-2022-164446

Published: 2022

Journal Articles

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Peihao Zheng, Rui Liu, Teng Xu, Fan Yang, Shaomei Feng, Yuelu Guo, Lixia Ma, Hui Shi, Hongwei Yu, Biping Deng, Xiaoyan Ke, Kai Hu

Blood (2022) 140 (Supplement 1): 7548–7549.

https://doi.org/10.1182/blood-2022-168018

Published: 2022

Journal Articles

Secondary Humanized CAR T Cells Salvage Therapy Improves Survival of R/R DLBCL Patients Failed to Murine CD19-CAR T Cells Therapy

Hui SHI, Kai Hu, Xiaoyan Ke, Tong Wu

Blood (2021) 138 (Supplement 1): 4836.

https://doi.org/10.1182/blood-2021-150108

Published: 2021

Journal Articles

Clinical Nursing during CD4-Specific CAR T Cells Treatment for One Mycosis Fungoides Patient Improves Generalized Skin Lesion

NA Zhang, Kai Hu, Xiaoyan Ke

Blood (2021) 138 (Supplement 1): 4974.

https://doi.org/10.1182/blood-2021-151910

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma

Fan Yang, Hui Shi, Yang Lei, Ruiting Li, Teng Xu, Biping Deng, Tong Wu, Xiaoyan Ke, Kai Hu

Blood (2021) 138 (Supplement 1): 557.

https://doi.org/10.1182/blood-2021-146767

Published: 2021

Journal Articles

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Blood (2021) 138 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2021-149861

Published: 2021

Journal Articles

Auto Hematopoietic Stem Cell Transplantation Combined with Another Target Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Failure of Murinized CD19-CAR-T Therapy

Kai Hu, Fan Yang, Rui Liu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui Shi, Biping Deng, Xiaoyan Ke, Tong Wu

Blood (2021) 138 (Supplement 1): 657.

https://doi.org/10.1182/blood-2021-146801

Published: 2021

Journal Articles

B7-H6 Is Associated with Poor Prognosis and a Potential Therapeutic Target of T-Lymphoblastic Lymphoma

Lei Yuan, Lu Sun, Yu Zhao, Hongmei Jing, MD PhD, Xiaoyan Ke, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-139146

Published: 2020

Journal Articles

Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-136475

Published: 2020

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134611

Published: 2020

NARROW

CAR T- Cell Therapy Provides an Opportunity for Further Consolidation Treatment for Relapsed or Refractory Adult Burkitt Lymphoma Patients

A Compilation of Experiences in Utilizing CAR-T Cell Therapy for Richter's Transformation

Assessment of Activities of Daily Living (ADL)Scale Can be Used to Predict Overall Survival after CAR-T Cell Therapy in Elderly Patient(over 70 years of age) with Refractory/Relapsed B-Cell Lymphoma

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Efficacy and Safety of Autologous Stem Cell Transplantation Combined with Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Refractory/Relapsed B-Cell Lymphoma

Evaluating the Impact of Cryopreservation of PBMCs on CAR-T Therapy Efficacy and Safety in DLBCL Patients: An Informative Approach to Optimize Manufacturing Strategies

The Mini-Teddi-R Treatment Demonstrated a High Rate of Remission in Patients with DLBCL Involving the CNS Who Had Previously Been Exposed to BTK Inhibitors

Efficacy and Safety of Zanubrutinib-Containing Regimens in Patients with Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma

Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy

Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities

Secondary Humanized CAR T Cells Salvage Therapy Improves Survival of R/R DLBCL Patients Failed to Murine CD19-CAR T Cells Therapy

Clinical Nursing during CD4-Specific CAR T Cells Treatment for One Mycosis Fungoides Patient Improves Generalized Skin Lesion

Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning Including Donor Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Auto Hematopoietic Stem Cell Transplantation Combined with Another Target Humanized CAR-T Cells for Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Failure of Murinized CD19-CAR-T Therapy

B7-H6 Is Associated with Poor Prognosis and a Potential Therapeutic Target of T-Lymphoblastic Lymphoma

Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only